Cue Biopharma, Inc.
CUE
CUE: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
moreShow CUE Financials
Recent trades of CUE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CUE's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 29, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 25, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides Jul. 18, 2023
-
Patent Title: Tgf-β polypeptides Jul. 04, 2023
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 20, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
-
Patent Title: Methods for modulating an immune response Oct. 25, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 02, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 05, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jun. 28, 2022
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Sep. 14, 2021
-
Patent Title: Methods for modulating an immune response Aug. 31, 2021
-
Patent Title: Methods for modulating an immune response Feb. 23, 2021
-
Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Feb. 23, 2021
Federal grants, loans, and purchases
Followers on CUE's company Twitter account
Number of mentions of CUE in WallStreetBets Daily Discussion
Recent insights relating to CUE
Recent picks made for CUE stock on CNBC
ETFs with the largest estimated holdings in CUE
Flights by private jets registered to CUE